Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevasiranib maintenance therapy in AMD
NCT00557791Phase 3Withdrawn
- Sponsor
- OPKO Health
- Start
- Nov 2009
- Primary completion
- Jul 2011
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
01
Overview
A Phase 3 trial of bevasiranib in exudative age-related macular degeneration, sponsored by OPKO Health. Planned start Nov 2009; status: withdrawn.
02
Drugs
bevasiranib
03
Conditions
exudative age-related macular degeneration
Beyond the preview
Go deeper on NCT00557791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00557791.